SCHEMBL6982192

SCHEMBL6982192

CS(=O)(=O)c1cc(N2CCCC(F)(NS(=O)(=O)c3cccc(C#N)c3)C2=O)ccc1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 4/20 0.38
ACLY P53396 2/20 0.37
CTSG P08311 1/20 0.36
CMA1 P23946 1/20 0.36
CNR2 P34972 1/20 0.36
PARG Q86W56 2/20 0.35
SLC6A9 P48067 1/20 0.34
NSD2 O96028 1/20 0.34
PTGES2 Q9H7Z7 1/20 0.34
USP2 O75604 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
PGR P06401 1/20 0.33
HIF1A Q16665 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MCHR1 Q99705 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679644 0.91 F10 (0.45) F10ACLYCTSGCMA1PARG
SCHEMBL6985447 0.88 F10 (0.45) F10PGR
SCHEMBL6985663 0.85 F10 (0.45) F10SLC6A9SMN1; SMN2
SCHEMBL6980681 0.84 F10 (0.45) F10ACLYCTSGCMA1PARG
SCHEMBL6989555 0.84 F10 (0.43) F10MAPK1
SCHEMBL6986546 0.83 F10 (0.42) F10ACLYUSP2SMN1; SMN2
SCHEMBL6988024 0.79 F10 (0.45) F10ACLYPGRTSHRSMN1; SMN2
SCHEMBL4681110 0.78 F10 (0.53) F10
SCHEMBL6985337 0.78 LMNA (0.40) F10CNR2SLC6A9
SCHEMBL4684735 0.77 F10 (0.54) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337251-A1 MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2003-08-27 EP disclosed
WO-2002102380-A1 MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2002-12-27 WO disclosed